Register for TECENTRIQ Updates
Sign up to receive the latest information about TECENTRIQ
You are now registering for information that is intended for
US healthcare professionals.
By registering at this site, you certify that you are a healthcare professional licensed in the United States or its territories and are indicating that you wish to receive information about TECENTRIQ, TECENTRIQ.com, other Genentech Oncology products, and related disease education. Genentech’s intent is to provide information only to healthcare professionals licensed in the United States or its territories who would likely be treating patients within the FDA-approved indications for this product.
Thank you for registering for TECENTRIQ updates
Registration is complete.
We have received your request, and you are now registered to receive updates about TECENTRIQ (atezolizumab), TECENTRIQ.com, other Genentech Oncology products, and related disease information.
The information you provided in this registration form will be used in accordance with Genentech Privacy Policy. Genentech will not sell, rent, or otherwise distribute your name and any personally identifiable information outside of Genentech and its agents. Also, any information or suggestions you provide regarding the content of any Genentech website, published document, or product will be handled in accordance with our Copyright Statement.
If you have any questions about the Genentech Privacy Policy or the information practices of our sites, you may contact us by email at privacy.office@gene.com or by mail at:
Genentech, Inc.
Attn: Privacy Office
1 DNA Way
South San Francisco, CA 94080